Legend Biotech stock
LEGNNASDAQLegend Biotech Corporation, HealthcareISIN US52490G1022
37Score 37 out of 100, Weak
Price and trend
41 / 100
Price history
−41% in one yearThe chart shows daily closes over 6 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 16% below it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 47).
The price is 49% below its 52-week high. Largest decline in 6 years: 78% (July 2023 to February 2026).
Chart figures for advanced users
- SMA 50$19.66
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$22.19
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)47
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.65
- The lowest closing price of the last twelve months.
- Resistance$36.28
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Legend Biotech Corporation belongs to the Biotechnology industry (United States) and, with a market value of $3.43B, is number 93 of 296 companies in its industry on MEQIRI.
- American depositary receipt (ADR): 1 ADR = 2 shares.
- In fiscal 2025 it reported revenue of $1.03B (up 64% year on year) and a loss of $296.8M.
Show more
- MEQIRI Score 37 out of 100 (Weak): rank 601 of 714 in Healthcare, median 53.
- Our model puts fair value at $6.03, with the price 224% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 68.8% a year since 2020, Biotechnology median 19.7%.Growth 70
- More cash than debtCash $852.5M, financial debt $167.4M.Stability 54
Weaknesses
- DilutionShare count up 56% since 2020.Capital allocation 24
- Above fair valuePrice 224% above the fair value of $6.03.Valuation 20
- Loss-makingLoss of $215K over the last 12 months.Fundamentals 22
Its standout strength is growth, while fundamentals and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 40 to 37.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
- price far below its 52-week high
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $4.02 and expensive above $12.07 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $5.55, at 8.4% it would be $6.72.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 49.5% on the twelve months before. Revenue has grown strongly since 2017, at around 60% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 60%, operating −13%, net −29%. Last 12 months: net 0%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 9 Mar 2027in 117 days
- Last reported
- 10 Nov 2026above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −0.040.0%
- Revenue
- $1.44B0.0%
- Earnings per share
- 0.540.0%
- Revenue
- $1.75B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: 0.0%No guidance change: gross margin on net product sales expected in the lower 50% range in the third quarter and in the mid-50% range in the fourth quarter, tax rate in the high 20% range.
“However, it is important to realize that there is still likely to be quarter-to-quarter variability in gross margin, and we expect Q3 gross margin on net product sales to be in the lower 50% range with a rebound into the mid-50% range anticipated for Q4.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 11 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 4 insiders sold, $479,616 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Sanders Corazon (Corsee) D.Sale
29 Sept 2026, Board
- Shares
- 27,370
- Price
- $9.46
- Value
- $258,920
- Santos Carlos ESale
21 Sept 2026, Chief Financial Officer
- Shares
- 5,430
- Price
- $9.14
- Value
- $49,630
- Casey Patrick JohnSale
30 Jun 2026, Board
- Shares
- 6,000
- Price
- $14.80
- Value
- $88,800
Show 1 more
- Huang YingSale
25 Jun 2026, Chief Executive Officer
- Shares
- 5,566
- Price
- $14.78
- Value
- $82,265
Shares and prices per ordinary share as filed with the SEC, not per depositary receipt (1 ADR = 2 shares).
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Legend Biotech
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Enliven TherapeuticsELVN $3.77B45
- Iovance BiotherapeuticsIOVA $3.74B43
- Denali TherapeuticsDNLI $3.72B37
- Viking TherapeuticsVKTX $3.63B34
- Arcutis BiotherapeuticsARQT $3.59B62
- Viridian TherapeuticsVRDN $3.55B47
- CelcuityCELC $3.55B28
- Dyne TherapeuticsDYN $3.37B36
ETFs that hold Legend Biotech
Held by 33 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Genomics & Biotechnology UCITS ETFGN0M | 2.40% | 0.50% | €127.06M |
| Harbor Health Care UCITS ETF AccW311 | 1.82% | 0.89% | €11.61M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.14% | 0.35% | €1.21B |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.08% | 0.30% | €134.65M |
| HSBC MSCI China UCITS ETFH4ZP | 0.07% | 0.28% | €865.21M |
| Deka MSCI China ex A Shares UCITS ETFEL46 | 0.07% | 0.65% | €74.12M |
| Amundi Core MSCI Emerging Markets UCITS ETF EUR DistAEMD | 0.02% | 0.18% | €9.12B |
| HSBC MSCI AC FAR EAST ex JAPAN UCITS ETF USDH411 | 0.02% | 0.45% | €400.29M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Jun 2021)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.